What: “Effective and Practical Strategies for Prosecuting and Litigating Biotech Patents in an Increasingly Uncertain Legal Environment” American Conference Institute’s 14th Advanced Forum on Biotech Patents The ongoing implementation of the America Invents Act and a massive upheaval of subject matter patentability signal that this continues to be a period of intense uncertainty for the biotechnology […]

The BIO 2012 convention in Boston, which ran June 18-21 in Boston pulled down a fair number of tweets in the process. Here are some we noticed: Mike Spear ‏@mikesgene @erinatbio #bio2012 payed off for us. BIORadio gave me a chance to speak with researchers and gov’t funders we haven’t tracked down at home. BIOIntl […]

After an exhausting time at BIO 2012, we can finally call it a wrap.  Here’s a sampling of the reporting around the blogosphere on the convention: Julie M. Donnelly at the Boston Business Journal gave the final numbers for BIO 2012: official tally of 16,505 attendees, down from the 22,000 in 2007. Total economic benefit […]

A panel discussion at BIO 2012 pondered the questions as to whether the America Invents Act (AIA) provides a new option replacing patents to secure freedom-to-operate for internally used innovations in biotechnology. Amendments to 35 U.S.C. Section 273 provide for prior user rights, which protect trade secret owners against patent infringement lawsuits. Therefore, if a company […]

“The relationship between IPRs and biopharmaceutical innovation is together with copyright on the internet perhaps the most contentiously debated topic in the literature.” ~ “Taking Stock: the Gains of Global Biotechnology Research from IPRs” Proponents argue that IPRs are essential to pharmaceutical and biotechnological innovation and provide innovators with the necessary incentives to continue to […]

Patent law is essential to industry and commerce, whether creating new markets and technologies through “creative destruction” and “disruptive innovation” or evolving and improving those that already exist. Cases involving these patents, however, require a judiciary well-informed enough to understand the differences between them. In addition, disruptive innovations in biotechnology can raise questions traditionally addressed […]

As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan.  During the 2012 BIO International Convention, a full-day of program has been devoted to China and will target both Chinese […]

For the fourth year in a row, BIO is working with bloggers and reporters from around the country (and Canada) to provide attendees with an inside look of what’s happening at the 2012 BIO International Convention in Boston. Be sure to check out their coverage on BIOtechNOW throughout the event and at their blogs: Biotech Blog: Yali Friedman & […]